Ata Initial Di Short Acting Adh

---
name: ata-initial-di-short-acting-adh
description: Suggests initial therapy for diabetes insipidus utilizes short-acting aqueous ADH, allowing safer use in the vast majority of cases where DI resolves spontaneously. Triggers include: new diabetes insipidus diagnosis requiring initial therapy, use when starting diabetes insipidus treatment.
---

# Initiate diabetes insipidus therapy with short-acting aqueous ADH

## STEP 1 — Gather Information
Collect history of polyuria, urine output, serum and urine osmolarity, serum sodium, weight, recent neurosurgery or head trauma, medication list; assess for transient DI risk. If DI is suspected based on polyuria (>3.5 L/24h in 70kg) and inappropriately dilute urine, proceed to confirmation.

## STEP 2 — Rule In / Rule Out
Perform water deprivation test or check serum osmolarity >295 mOsm/L with urine osmolarity <600 mOsm/L; if confirmed DI, rule out primary polydipsia (by checking urine concentration after desmopressin). If DI is confirmed and not primary polydipsia, proceed to classify DI type.

## STEP 3 — Classify or Stratify
Determine if DI is likely transient (e.g., post-operative within 2 weeks) or permanent; also assess for adipsic DI (lack of thirst). If transient DI suspected, initiate short-acting aqueous ADH; if permanent DI, consider long-acting therapy but short-acting may still be used initially.

## STEP 4 — Decide
Start short-acting aqueous ADH (vasopressin) at low dose (e.g., 0.5-1 IU IV hourly) or subcutaneous, titrate to achieve urine output <3 L/24h and serum Na 135-145, monitor q4-6h, educate patient on overdose signs, plan weekly water load test to assess need for continued therapy. Adjust dose based on response; discontinue if DI resolves.

## Clinical Guardrails / Mimics / Pitfalls
Do not use longer-acting DDAVP as initial therapy in settings where DI may resolve; avoid fixed schedules without monitoring; do not ignore hyponatremia signs; do not prescribe DDAVP in adipsic DI without close sodium monitoring; do not use in patients with known hypersensitivity to vasopressin.

## Concrete Clinical Example
45-year-old woman post-transsphenoidal resection of pituitary adenoma presents with urine output 5 L/day, serum Na 152, urine osm 120 mOsm/L; serum osm 302 mOsm/L. Water deprivation test confirms DI. She is started on intravenous vasopressin 0.5 IU hourly, adjusted to maintain urine output 2.5 L/day and serum Na 138. After 5 days, urine output decreases to 1.8 L/day with fluid restriction; a trial off vasopressin shows no polyuria, so therapy is discontinued.

**Source:** Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118